Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR1 N546K |
| Therapy | Fexagratinib + Pictilisib |
| Indication/Tumor Type | neuroblastoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR1 N546K | neuroblastoma | sensitive | Fexagratinib + Pictilisib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Fexagratinib (AZD4547) and Pictilisib (GDC-0941) resulted in greater inhibition of FGFR1 signaling, cell invasion, and colony formation compared to Fexagratinib (AZD4547) alone in neuroblastoma cell lines expressing FGFR1 N546K in culture (PMID: 35488346). | 35488346 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (35488346) | FGFR1 is a potential therapeutic target in neuroblastoma. | Full reference... |